Genprex receives Nasdaq delisting determination; plans to request hearing panel review
Genprex received a delisting determination from Nasdaq's Listing Qualifications Staff on June 10, 2026, after the company's common stock closed below the $1.00 minimum bid price for 30 consecutive business days and the company was deemed ineligible for a compliance period due to a reverse stock split effected on October 21, 2025. The company intends to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay delisting pending the hearing outcome. Genprex plans to take steps to regain compliance, including potentially effecting another reverse stock split, though no assurance exists the panel will grant continued listing.
Key facts
- Delisting determination issued June 10, 2026, by Nasdaq Listing Qualifications Staff
- Stock closed below $1.00 per share for 30 consecutive business days
- Company ineligible for 180-day compliance period due to reverse stock split on October 21, 2025
- Company intends to request hearing before Nasdaq Hearings Panel
- Bid Price Requirement: minimum $1.00 per share under Nasdaq Listing Rule 5550(a)(2)
- Request for hearing will automatically stay suspension or delisting pending panel decision
- To regain compliance: closing bid price must reach at least $1.00 for minimum of 10 consecutive business days
Why it matters
A delisting determination has been issued and Genprex's continued listing on Nasdaq is now contingent on a hearing panel decision; failure to regain bid-price compliance or maintain the listing could materially reduce the stock price, impair access to capital markets, and harm investor confidence.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-12. Not investment advice. View the source filing on SEC.gov →